Anti-p19 antibody treatment exacerbates lyme arthritis and enhances borreliacidal activity

Sara Heil Peterson, Dean T. Nardelli, Thomas F. Warner, Steven M. Callister, Jose R. Torrealba, Ronald F. Schell

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Considerable effort has been made to elucidate the mechanism of Lyme arthritis. We focused on p19, a cell cycle-regulating molecule, because it is known to inhibit cell cycle division of T lymphocytes which may be responsible for the induction of arthritis. We show that anti-p19 antibody treatment enhances the inflammatory response normally detected at the tibiotarsal joints of Borrelia burgdorferi-vaccinated and Borrelia bissettii challenged mice. Specifically, anti-p19 antibody treatment augmented the severity of inflammation within the synovial and subsynovial tissue. Moreover, treatment with anti-p19 antibody caused severe erosion of cartilage and bone with ankle joint destruction. In addition, anti-p19 antibody treatment of Borrelia-vaccinated and -challenged mice enhanced the borreliacidal antibody response, especially against the vaccine isolate. The novel activities of anti-p19 antibody show that p19 may be an important therapeutic site for the treatment of Lyme arthritis.

Original languageEnglish (US)
Pages (from-to)510-517
Number of pages8
JournalClinical and Vaccine Immunology
Volume14
Issue number5
DOIs
StatePublished - May 2007

Fingerprint

Lyme Disease
Anti-Idiotypic Antibodies
Antibodies
Borrelia
Cell Cycle
Cells
Borrelia burgdorferi
Ankle Joint
T-cells
Cartilage
Arthritis
Antibody Formation
Vaccines
Joints
Erosion
Bone
Inflammation
T-Lymphocytes
Bone and Bones
Tissue

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Immunology
  • Immunology and Allergy
  • Microbiology (medical)

Cite this

Anti-p19 antibody treatment exacerbates lyme arthritis and enhances borreliacidal activity. / Peterson, Sara Heil; Nardelli, Dean T.; Warner, Thomas F.; Callister, Steven M.; Torrealba, Jose R.; Schell, Ronald F.

In: Clinical and Vaccine Immunology, Vol. 14, No. 5, 05.2007, p. 510-517.

Research output: Contribution to journalArticle

Peterson, Sara Heil ; Nardelli, Dean T. ; Warner, Thomas F. ; Callister, Steven M. ; Torrealba, Jose R. ; Schell, Ronald F. / Anti-p19 antibody treatment exacerbates lyme arthritis and enhances borreliacidal activity. In: Clinical and Vaccine Immunology. 2007 ; Vol. 14, No. 5. pp. 510-517.
@article{fec7511ba8ac43d49bdcc0d96e2e56f6,
title = "Anti-p19 antibody treatment exacerbates lyme arthritis and enhances borreliacidal activity",
abstract = "Considerable effort has been made to elucidate the mechanism of Lyme arthritis. We focused on p19, a cell cycle-regulating molecule, because it is known to inhibit cell cycle division of T lymphocytes which may be responsible for the induction of arthritis. We show that anti-p19 antibody treatment enhances the inflammatory response normally detected at the tibiotarsal joints of Borrelia burgdorferi-vaccinated and Borrelia bissettii challenged mice. Specifically, anti-p19 antibody treatment augmented the severity of inflammation within the synovial and subsynovial tissue. Moreover, treatment with anti-p19 antibody caused severe erosion of cartilage and bone with ankle joint destruction. In addition, anti-p19 antibody treatment of Borrelia-vaccinated and -challenged mice enhanced the borreliacidal antibody response, especially against the vaccine isolate. The novel activities of anti-p19 antibody show that p19 may be an important therapeutic site for the treatment of Lyme arthritis.",
author = "Peterson, {Sara Heil} and Nardelli, {Dean T.} and Warner, {Thomas F.} and Callister, {Steven M.} and Torrealba, {Jose R.} and Schell, {Ronald F.}",
year = "2007",
month = "5",
doi = "10.1128/CVI.00005-07",
language = "English (US)",
volume = "14",
pages = "510--517",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "5",

}

TY - JOUR

T1 - Anti-p19 antibody treatment exacerbates lyme arthritis and enhances borreliacidal activity

AU - Peterson, Sara Heil

AU - Nardelli, Dean T.

AU - Warner, Thomas F.

AU - Callister, Steven M.

AU - Torrealba, Jose R.

AU - Schell, Ronald F.

PY - 2007/5

Y1 - 2007/5

N2 - Considerable effort has been made to elucidate the mechanism of Lyme arthritis. We focused on p19, a cell cycle-regulating molecule, because it is known to inhibit cell cycle division of T lymphocytes which may be responsible for the induction of arthritis. We show that anti-p19 antibody treatment enhances the inflammatory response normally detected at the tibiotarsal joints of Borrelia burgdorferi-vaccinated and Borrelia bissettii challenged mice. Specifically, anti-p19 antibody treatment augmented the severity of inflammation within the synovial and subsynovial tissue. Moreover, treatment with anti-p19 antibody caused severe erosion of cartilage and bone with ankle joint destruction. In addition, anti-p19 antibody treatment of Borrelia-vaccinated and -challenged mice enhanced the borreliacidal antibody response, especially against the vaccine isolate. The novel activities of anti-p19 antibody show that p19 may be an important therapeutic site for the treatment of Lyme arthritis.

AB - Considerable effort has been made to elucidate the mechanism of Lyme arthritis. We focused on p19, a cell cycle-regulating molecule, because it is known to inhibit cell cycle division of T lymphocytes which may be responsible for the induction of arthritis. We show that anti-p19 antibody treatment enhances the inflammatory response normally detected at the tibiotarsal joints of Borrelia burgdorferi-vaccinated and Borrelia bissettii challenged mice. Specifically, anti-p19 antibody treatment augmented the severity of inflammation within the synovial and subsynovial tissue. Moreover, treatment with anti-p19 antibody caused severe erosion of cartilage and bone with ankle joint destruction. In addition, anti-p19 antibody treatment of Borrelia-vaccinated and -challenged mice enhanced the borreliacidal antibody response, especially against the vaccine isolate. The novel activities of anti-p19 antibody show that p19 may be an important therapeutic site for the treatment of Lyme arthritis.

UR - http://www.scopus.com/inward/record.url?scp=34250316572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250316572&partnerID=8YFLogxK

U2 - 10.1128/CVI.00005-07

DO - 10.1128/CVI.00005-07

M3 - Article

C2 - 17360856

AN - SCOPUS:34250316572

VL - 14

SP - 510

EP - 517

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 5

ER -